Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166523 · ClinicalTrials.gov registry record · NA
Radicle Energy™ 24_RCA: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes
A NA study of Fatigue, sponsored by Radicle Science.
- Completed
- Registry status
- NA
- Development phase
- 501
- Enrollment target
- 1
- Study location
NCT07166523: Completed NA study of Fatigue, sponsored by Radicle Science.
NCT07166523 is a NA study of Fatigue that has completed, run by Radicle Science. The registered enrollment target is 501 participants, above the 214-participant average among 109 other Fatigue trials with a reported enrollment target (134% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166523, a NA study of Fatigue, has completed, sponsored by Radicle Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 501 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes
Primary Outcome
Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Energy Product Placebo Control
- DIETARY_SUPPLEMENT Energy Active Product 1
Study Locations (1)
California
- Radicle Science Inc. - Del Mar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2025-11-26 |
| Phase | NA |
What the finished NCT07166523 record still lists
NCT07166523 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 214-participant average among 109 other Fatigue trials with a reported enrollment target (134% higher).
The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Energy Product Placebo Control is the first listed.
NCT07166523 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07166523 about?
NCT07166523 is a clinical study titled "Radicle Energy™ 24_RCA: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes". A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes
What is the current status of trial NCT07166523?
This trial is currently completed. It is a NA study. The enrollment target is 501 participants. The study started on 2025-09-09. Estimated completion is 2025-11-26.
What conditions does trial NCT07166523 study?
This clinical trial studies the following conditions: Fatigue.
What interventions are being tested in trial NCT07166523?
The interventions under investigation include: Energy Product Placebo Control (DIETARY_SUPPLEMENT), Energy Active Product 1 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07166523?
This trial is sponsored by Radicle Science, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07166523 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07166523's enrollment target sits among peer trials
501 7th of 109 higher than 103 of 109 other Fatigue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fatigue and Cognitive Demand With Aging
RECRUITING · NA
-
Behavioral and Neural Correlates of Post-Stroke Fatigue
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
The Fit With Us Study
RECRUITING · NA
-
Increasing Physical Activity for Adults With Multiple Sclerosis (MS)
RECRUITING · NA
-
Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI